| Previous Section | Index | Home Page |
19 July 2007 : Column 641W—continued
PSSEX1 Expenditure Return
Mr. Stephen O'Brien: To ask the Secretary of State for Health what information is gathered in the PSSEX1 Expenditure Return. [148839]
Mr. Ivan Lewis: The personal social services expenditure return (PSSEX1) is collected by The Information Centre for health and social care, and shows data from local authorities on current expenditure and unit costs on personal social services for adults and children, both nationally and for individual authorities. Expenditure data is presented on a gross and net basis, and is also split between authorities’ own provision and provision by others. It is also broken down by client groups:
older people (including those with disabilities);
children and family services (including children with disabilities);
learning disabled adults;
physically disabled adults;
mentally ill adults;
asylum seekers; and
other adult services.
Services are analysed between residential day and domiciliary provision, and the costs of assessment and care management are also identified.
The latest available data are on 2005-06 Expenditure report, which can be accessed at:
Smoking
Sandra Gidley: To ask the Secretary of State for Health how much was spent on (a) prevention and (b) campaigns designed to assist people to stop smoking in each year since 1997. [150958]
Dawn Primarolo: The available information is set out in the tables.
The Department does not centrally collect information on additional local spend on tobacco control including campaigns.
| Campaign advertising expenditure for smoking | |
| £ million | |
| Financial allocations to the NHS for stop smoking services | |
| £ million | |
| HAZ = Health action zones. (1) HAZs only. (2) 10 million HAZs, 10 million HAs. (3) £3 million in 2001-02 and 2002-03 for smoking in pregnancy initiative. | |
Smoking: Health Hazards
Sandra Gidley: To ask the Secretary of State for Health how much was spent by his Department on treating smoking related diseases in each year since 1997, broken down by health authority. [150959]
Dawn Primarolo: Data are not collected in the format requested.
In the White Paper “Smoking Kills” a cost of up to £1.7 billion per year was identified as the cost to the national health service of treating smoking related diseases. This was based on research published by the Health Education Authority in 1997. These documents are available in the Library.
Smoking: Public Places
Philip Davies: To ask the Secretary of State for Health what assessment his Department has made of the likely effect of the smoking ban on (a) the number of pubs operating in England and (b) employment in that sector. [150754]
Dawn Primarolo: An assessment of the costs and benefits of smokefree legislation is set out in the final Regulatory Impact Assessment (RIA) that was published by the Department in December 2006.
Partial RIAs were included within the “Consultation on the Smokefree Elements of the Health Improvement and Protection Bill” published in 2005 and in “Smoke-free Premises and Vehicles: Consultation on proposed regulations to be made under powers in the Health Bill” published in 2006. Both consultation exercises invited stakeholders to provide comments on the partial RIA as well as the proposals in the consultation. Responses from stakeholders assisted the Department in producing the final RIA.
All documents referred to are available in the Library.
Solvents: Misuse
Tim Loughton: To ask the Secretary of State for Health what assessment he has made of the number of children who have (a) died and (b) been brain damaged by volatile substance abuse in each of the last 10 years. [150335]
Dawn Primarolo: The number of young people under the age of 18 who have died from volatile substance misuse in the last 10 years is shown in the following table.
| Number of children | |
| Source: Statistics from St. George’s University of London | |
Information regarding young people who have been brain damaged by volatile substance abuse in the last 10 years is not collected centrally.
Tim Loughton: To ask the Secretary of State for Health who sits on the stakeholder group set up under the Volatile Substance Abuse Framework. [150375]
Dawn Primarolo: A stakeholder group made up of key players in the field, was set up in December 2004 to develop and implement the National Framework for Volatile Substance Abuse. The group was revised in December 2006 to include key departments across Government. It is chaired by the Department.
Prior to the Government machinery of changes, stakeholders included:
Department of Health
Home Office
Department for Education and Skills
Office of the Deputy Prime Minister
Department of Trade and Industry
National Treatment Agency
Local Government Office—Young People Lead
Plus the Welsh Assembly and Scottish Executive
ReSolv
Solv-It
National Children’s Bureau
Drug Education Forum
St. George’s University of London
British Aerosols Manufacturing Association
Trading Standards
SC Johnson
Swan
Ronson
LP Gas Association
Shell UK
Statins
Bob Spink: To ask the Secretary of State for Health what assessment he has made of the side-effects of statins; and if he will make a statement on the use of statins under the new National Institute for Health and Clinical Excellence guidelines. [149639]
Ann Keen: The Medicines and Healthcare product Regulatory Agency (MHRA), with independent advice from the Commission on Human Medicines, assesses the balance of risks and benefits of all medicines at the time of initial licensing and throughout their use in clinical practice.
The MHRA reviews new safety information as it emerges, including reports of suspected adverse drug reactions from healthcare professionals and the public, published scientific literature (including clinical trials and epidemiological studies), and periodic safety update reports from pharmaceutical companies. When necessary, the MHRA takes regulatory action to minimise risks and communicate new advice on the safe use of medicines to healthcare professionals and the public.
Statins are generally well tolerated but, as with all medicines, side effects can occur. Serious side-effects, however, are rare. The recognised side effects of licensed medicines are listed in their product information, provided for healthcare professionals. All new medicines are now also required to have patient information leaflets which provide information on how to use the medicine, and on their side effects.
In January 2006 the National Institute for Health and Clinical Excellence published a health technology appraisal of statins which found that they were both clinically and costs effective for prescription to people at a 20 per cent. ten-year risk of developing cardiovascular disease, as well as for patients with established disease. That finding has been repeated in their draft guideline on lipid modification, published for consultation on 27 June.
Bob Spink: To ask the Secretary of State for Health what research he has commissioned into the long-term effects of the use of statins by people over the age of 50. [149728]
Ann Keen: None, although the Department has through both its policy research and health technology assessment programmes funded research concerned with the use and value of statins in health care.
The Medical Research Council (MRC) is one of the main agencies through which the Government support medical and clinical research. The MRC has funded studies that show cholesterol-lowering statin treatment reduces the risk of heart attacks and strokes by at least one-third as well as lowering the need for arterial surgery, angioplasty and amputations.
In particular the Heart Protection Study (HPS), funded by the MRC and the British Heart Foundation, is the biggest world-wide study of cholesterol lowering therapy. The HPS which reported in July 2002 found significant benefits of statins to people aged over 70 as well as for younger people.
Bob Spink: To ask the Secretary of State for Health what assessment he has made of the effectiveness of statins in lengthening quality assured life years. [149730]
Ann Keen:
Quality adjusted life years (QALYS) and life-years gained are both measures used by researchers, including the National Institute for Health
and Clinical Excellence (NICE), in evaluating the benefits of treatments and interventions.
In January 2006 the National Institute for Health and Clinical Excellence published a health technology appraisal of statins which found that they were both clinically and cost-effective for prescription to people at a 20 per cent. 10-year risk of developing cardiovascular disease, as well as for patients with established disease. That finding has been repeated in their draft guideline on lipid modification, published for consultation on 27 June.
West Sussex Primary Care Trust: Public Appointments
Mr. Gibb: To ask the Secretary of State for Health when he expects a director of public patient involvement to be appointed to the West Sussex primary care trust. [149411]
Ann Keen: The appointment of a director of public patient involvement is a matter for West Sussex primary care trust.
| Index | Home Page |